Drug Run

Singh, Seema
May 2007
Red Herring;5/28/2007, Vol. 4 Issue 17/18, p13
Trade Publication
The article explores how Indian drug companies will be affected by the April 30, 2007 ruling of the U.S. Supreme Court that makes it easier to invalidate patents and raises the threshold for obtaining patents. Indian drug companies, which produce over 22 percent of the world's generic drugs, according to consulting firm KPMG, are already challenging U.S. drug patents in order to sell in the U.S. market. The Court ruling means patent challenges could become an even more potent business strategy for generics producers. It is stated that Dr. Reddy's is one example of Indian drug makers' success in reverse-engineering patent-protected medicines.


Related Articles

  • Court ruling imperils pharma patents. Iskowitz, Marc // Medical Marketing & Media;Jun2007, Vol. 42 Issue 6, p10 

    The article reports on the negative impact of the decision of the Supreme Court on the case called KSR International Co. v. Teleflex on pharmaceutical companies on the patent front in the U.S. The court rejected a test used by the Court of Appeals for the Federal Circuit to check for...

  • TEVA, NAUTILUS, AND CHANGE WITHOUT CHANGE. Rantanen, Jason // Stanford Technology Law Review;Sep2015, Vol. 18 Issue 3, p375 

    Over the past several years, the Supreme Court has been remarkably active in patent law. Out of all those decisions which have touched almost every aspect of patent law, the ones with the greatest potential to shake its foundations were the Court's opinions addressing claim meaning. "The name of...

  • Canada to allow production of generic AIDS drugs.  // Nature Reviews Drug Discovery;Nov2003, Vol. 2 Issue 11, p854 

    Reports that Canadian Prime Minister-elect Paul Martin, has endorsed plans for the federal government to excuse poor countries from patent rules. Allowance for Canadian generic-drug makers to supply cheap medicines to developing countries undergoing health crises; Deal of the World Trade...

  • High court rules on 'pay-for-delay' deals. HOLLAND, JESSE J. // Buffalo Law Journal;6/24/2013, Vol. 85 Issue 34, p4 

    The article reports on the 5-3 votes of the justices in the U.S. Supreme Court allowing the government to inspect and challenge the "pay-for-delay" deals between pharmaceutical corporations and their generic drug competitors.

  • High Court Weighs In on Rx Focus.  // Chain Drug Review;7/8/2013, Vol. 35 Issue 11, p41 

    The article informs that the U.S. Supreme Court has striked the pharmaceutical industry after ruling that antitrust regulators should be able to challenge arrangements allowing rival drug makers to delay the sale of a generic drug.

  • Patent expirations spell big changes for generic industry. Cassell, Dana K. // Drug Topics;8/6/2001 Supplement, Vol. 145 Issue 15, p9 

    Focuses on the increase of patent expirations among pharmaceutical industries in the United States. List of top eight drugs going off patent before December 2005; Delay of patent expiration due to court trials; Plan of an educational campaign on safety and efficacy of generic drugs.

  • Court makes it easier to invalidate patents. Yost, Pete // Buffalo Law Journal;5/3/2007, Vol. 79 Issue 36, p20 

    The article reports on the ruling of the U.S. Supreme Court that makes it easier to invalidate patents whether a claimed invention is obvious and unworthy of patent protection. It cites the basis of the Court of Appeals for its ruling on the case KSR International Co. versus Teleflex Inc. It...

  • Supreme court set to rule on obviousness. Owens, Joanna // Nature Reviews Drug Discovery;Jan2007, Vol. 6 Issue 1, p16 

    The article speculates on the implications for the pharmaceutical and biotechnology sectors following the Supreme Court's hearing on technology and method patent cases. The example of KSR International and Teleflex case is cited. The doctrine of non-obviousness as well as the use of the...

  • Every benefits with court ruling on generic drug testing. Choudhury, Pravat // Marketing News;9/2/1983, Vol. 17 Issue 18, p6 

    The author reflects on the beneficial effect of a ruling issued by the U.S. Supreme Court requiring generic drugs to undergo the same screening and approval procedures as required to brand name products by the U.S. Food and Drug Administration (FDA). Generic drug products are defined as drugs...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics